Your browser does not support iframes.
We intend to do this by increasing access to vital medicines through affordability, innovation and improved treatment outcomes. Our aim is to offer fresh hope to patients through discovery and development of novel biopharmaceuticals based on new targets and pathways. In short, we are working to build a balanced portfolio of innovative Biologics, Biobetters and Biosimilars that is aligned to our core therapeutic areas of expertise.
We have a track record of success in the biologics arena, having launched Granix® (tbo-filgrastim) in the US and Lonquex® (lipegfilgrastim) in Europe and we plan to continue building on that success by turning key insights into novel and highly differentiated therapies. Our biologics pipeline includes multiple product candidates in various stages of development including both novel monoclonal antibody therapeutics and albumin fusion technology-based programs.
We are furthering the discovery and development of novel biopharmaceuticals for the treatment of numerous diseases. Using proprietary novel technologies and validated targets, we are developing new drug candidates that align with key therapeutic areas. In central nervous system and pain disorders, our efforts are focused on the development of an anti-CGRP monoclonal antibody for the prevention of chronic and high frequency episodic migraine. In respiratory, we are working to reduce inflammatory processes by interfering with known pathways for asthma exacerbation.Our biologics discovery group is also working on platforms and technologies that are designed to enhance the specificity and delivery of antibodies in a way that will maximize their effect, particularly in relation to central nervous system (CNS) targets.
Reslizumab is an investigational humanized monoclonal antibody (mAb) against interleukin-5 (IL-5). IL-5 has been shown to play a crucial role in the maturation, growth and chemotaxis (movement) of eosinophils, inflammatory white blood cells implicated in a number of allergic diseases.Reslizumab has completed its Phase III clinical development program in patients with eosinophilic asthma and we hope to submit reslizumab for approval by the regulatory authorities in 2015. Discover more about our respiratory program >
TEV-48125 is a monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), a well-validated target in migraine. It is currently in Phase IIb clinical trials for the prevention of episodic and chronic migraine. Discover more about our migraine program >
Our R&D group also spearheads the development of next-generation peptide and protein based therapeutics across a variety of therapeutic categories. Our aims are improved efficacy, reduced dosing frequency and enhanced patient safety and convenience. Through the use of advanced technology platforms, we can improve and expand the use of established biopharmaceuticals as we meet the challenge of optimizing complex manufacturing processes.
We are a leader in the development of Biosimilar medicines. As the equivalent to generics for name-brand biologics, Biosimilars offer patients and healthcare systems access to high-cost medicines at a more affordable level. Our R&D group has adopted a selective approach to developing Biosimilars, and applies novel thinking in our determination to make these medicines available to those patients who need them.